Liquidia up 7% after announcing additional Phase 3 Inspire trial findings
Liquidia Technologies last night announced additional safety and exploratory endpoint findings at the two-month timepoint for the Phase 3 Inspire trial. Nicholas Hill, Chief Pulmonary, Critical Care & Sleep Division and Professor of Medicine at Tufts University School of Medicine and Inspire Principal Investigator, presented the data at the opening plenary session of the International Society for Heart & Lung Transplantation meeting. Liquidia is pursuing approval of LIQ861, an inhalation dry powder formulation of treprostinil, as an alternative to current inhaled treprostinil therapy for the treatment of patients with pulmonary arterial hypertension. "The two-month results of the Inspire trial are promising for patients with PAH. Inhaled therapy offers the benefit of getting drug directly to the lungs and we are encouraged that the safety, tolerability and quality of life metrics suggest that LIQ861 is an attractive and more convenient therapy versus the currently available inhaled therapies," said Dr. Hill. The Inspire trial includes two groups of PAH patients. Most treatment emergent adverse events occurred in the add-on population and were observed mainly during initial exposure to LIQ861 at the 25mcg dose, the company said. "Overall, TEAEs observed were consistent with inhaled prostacyclins and considered mild to moderate, including cough, headache and throat irritation. No serious adverse events related to LIQ861 were observed during the two month period," it added. Shares of Liquidia Technologies are up 7%, or 72c, to $10.92 in morning trading.